None listed
Conditions
Brief summary
This study aims to evaluate the prevalence of people with bile acid malabsorption in a cohort of individuals with functional, chronic diarrhea in a health care setting. Each recruited participant will receive 14 days of cholestryramine. In addition, plasma samples will be collected to validate a novel plasma biomarker for specificity and sensitivity.
Interventions
Participants with functional chronic diarrhoea will receive 14 days of cholestyramine, a bile acid sequestrant in powder form, to drink dissolved in liquid according to manufacturer's guidelines: "QUESTRAN LITE should be taken mixed with water, juice or highly fluid foods. When mixing individual sachets for immediate use, place the contents of a 4g sachet of QUESTRAN LITE on the surface of 100-150mL water or fruit juice (200-300mL for an 8g sachet of QUESTRAN LITE). Mix immediately by stirring vigorously or preferably by shaking in a Questran Lite shaker. Continue stirring or shaking until mixture is even. After dosing, rinse the container to ensure full dose. Alternatively, QUESTRAN LITE may be mixed with highly fluid soups, pulpy fruits with a high moisture content (e.g., apple puree or crushed pineapple), or if care is taken to avoid excessive foaming, a carbonated beverage.. Specifically, 4g of cholestyramine is equivalent to 4.7g Questran Lite (prescription brand name) per day in the evening or morning, increasing it to up to 12g cholestyramine /14.1g of Questran Lite over 14 days. Begin with 4g cholestyramine (4.7 QUESTRAN LITE) in the morning or evening, increasing to the required maintenance dose over 2 to 4 weeks." There is no strict protocol since the dose has to be adjusted individually, with input from the medical officer, depending on tolerability. Adherence is not monitored, as it is a prescription drug, and there are no lab tests available for monitoring.
Sponsors
Study design
Eligibility
Inclusion criteria
BMI 17-37 Participants with a known diagnosis of IBS-D or Functional Diarrhoea (FD) Participants with a suspected diagnosis of IBS-D or FD, or chronic diarrhoea symptoms according to RomeIV criteria
Exclusion criteria
Current treatment with bile acid sequestrants Inability to give informed consent Known significant gastrointestinal disorder such as colorectal cancer, diverticulitis Coeliac disease Pregnancy Contraindications for bile-acid sequestrants Laxative use Those with symptoms atypical for functional gastrointestinal disease or where there is a high index of suspicion for other diagnoses (eg colorectal cancer, ischaemic colitis, infective colitis). Those with an acute health problem as determined through the biochemical blood panel